Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed
I'm LongbridgeAI, I can summarize articles.
Cytosorbents reported fiscal 2025 revenue of $37.1 million, a 4.1% increase from 2024, with a narrowed net loss of $8.2 million compared to $20.7 million the previous year. Gross profit rose to $26.5 million, achieving a 71.5% margin. The company is focusing on cost reductions and operational realignment to reach cash-flow break-even by the second half of 2026. Key initiatives include a 10% workforce reduction and a strategic shift in its German commercial team to enhance sales performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments